Indivior PLC $INDV is Mangrove Partners IM LLC’s Largest Position

Mangrove Partners IM LLC lifted its holdings in Indivior PLC (NASDAQ:INDV) by 20.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,742,434 shares of the company’s stock after purchasing an additional 469,766 shares during the period. Indivior comprises approximately 5.5% of Mangrove Partners IM LLC’s holdings, making the stock its biggest position. Mangrove Partners IM LLC owned approximately 1.99% of Indivior worth $66,120,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its position in shares of Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Jane Street Group LLC raised its position in shares of Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after purchasing an additional 958,132 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in shares of Indivior during the 2nd quarter valued at $768,000. ProShare Advisors LLC bought a new position in Indivior in the 2nd quarter worth $435,000. Finally, Geode Capital Management LLC boosted its holdings in Indivior by 1,122.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock worth $23,244,000 after buying an additional 1,447,939 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on INDV. Weiss Ratings raised Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, March 2nd. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. HC Wainwright boosted their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Morgan Stanley restated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Finally, Northland Securities set a $50.00 price objective on shares of Indivior in a report on Tuesday, January 20th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Indivior presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Insider Transactions at Indivior

In related news, Director Keith Humphreys bought 775 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 5,802 shares in the company, valued at $205,332.78. This trade represents a 15.42% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel A. Ninivaggi purchased 775 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director directly owned 16,923 shares in the company, valued at $598,904.97. This trade represents a 4.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 5,842 shares of company stock worth $203,342.

Indivior Stock Up 0.8%

INDV stock opened at $31.11 on Friday. Indivior PLC has a 52 week low of $8.64 and a 52 week high of $38.00. The firm has a market capitalization of $3.89 billion, a P/E ratio of 18.97 and a beta of 0.83. The company has a fifty day simple moving average of $33.73 and a two-hundred day simple moving average of $30.58.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The firm had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. As a group, analysts anticipate that Indivior PLC will post 1.22 EPS for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.